

1           **Metalloctanionic vesicles mediated enhanced singlet oxygen generation and**  
2                                   **photodynamic therapy of cancer cells**

3   Bunty Sharma<sup>1,2,a</sup>, Akhil Jain<sup>3,a</sup>, Lluïsa Pérez-García<sup>2,4,5\*</sup>, Julie A Watts<sup>3</sup>, Frankie J. Rawson<sup>3</sup>,  
4   Ganga Ram Chaudhary<sup>1</sup>, and Gurpreet Kaur<sup>1\*</sup>

5   <sup>1</sup> Department of Chemistry, Centre for Advanced Studies in Chemistry, Panjab University,  
6   Chandigarh-160014, India

7   <sup>2</sup> Division of Advanced Materials and Healthcare Technologies, School of Pharmacy,  
8   University of Nottingham, Nottingham NG7 2RD, UK

9   <sup>3</sup> Division of Regenerative Medicine and Cellular Therapies, School of Pharmacy, University  
10   of Nottingham, Nottingham NG7 2RD, UK

11   <sup>4</sup> Departament de Farmacologia, Toxicologia i Química Terapèutica, Facultat de Farmàcia i  
12   Ciències de l'Alimentació, Avda. Joan XXIII 27-31, Universitat de Barcelona, 08028  
13   Barcelona, Spain

14   <sup>5</sup> Institut de Nanociència i Nanotecnologia UB (IN2UB), Universitat de Barcelona 08028  
15   Barcelona, Spain

16  
17  
18   <sup>a</sup>These authors have contributed equally to this work.

19   \*corresponding authors: Gurpreet Kaur (email: [gurpreet14@pu.ac.in](mailto:gurpreet14@pu.ac.in))

20                                   Lluïsa Perez-Garcia (email: [mlperez@ub.edu](mailto:mlperez@ub.edu))

21

22 **Abstract:** In clinics, photodynamic therapy (PDT) is established as a non-invasive  
23 therapeutic modality for certain types of cancers and skin diseases. However, due to poor  
24 water solubility, photobleaching and dark toxicity of photosensitizers (PSs), further  
25 developments are required to improve the efficiency of PDT. Herein, we report the role of  
26 metallocatanionic vesicles (MCVs) in enhancing the phototoxicity of methylene blue (MB)  
27 against cancer cells. These MCVs were prepared by a facile and quick solution-solution  
28 mixing method using a cationic single-chain metallosurfactant (FeCPC I) in combination  
29 with the anionic sodium oleate (Na Ol). For singlet oxygen ( $^1\text{O}_2$ ) generation and PDT studies,  
30 two fractions FeCPC I:Na Ol (30:70) and (70:30) were chosen based on their long-term  
31 stability in aqueous media. A cationic PS MB was loaded into these vesicles. The MB-loaded  
32 MCVs 30:70 and 70:30 fractions enhanced the  $^1\text{O}_2$  generation by 0.10 and 0.40 fold,  
33 respectively, compared to MB alone. Upon illumination with a 650 nm laser, these MB-  
34 loaded V73 (70:30) and V37(30:70) MCVs significantly decreased the metabolic activity of  
35 MCF-7 cells by  $\leq 50\%$  at a concentration of  $0.75 \mu\text{M}$ . Furthermore, the SOSG assay revealed  
36 that the synthesized MCVs enhanced the intracellular  $^1\text{O}_2$  compared to MB alone. MB-loaded  
37 V73 MCVs showed the highest  $^1\text{O}_2$  mediated membrane damage and cell killing effect as  
38 confirmed by differential nuclear staining assay (DNS), which is attributed to the cellular  
39 uptake profile of different MCV fractions. Altogether this work shows the advantage of using  
40 these biocompatible and dual charge MCVs as promising delivery vehicles that can enhance  
41 the  $^1\text{O}_2$  generation from PS. This work endows the future application of these Fe-MCVs in  
42 magnetically guided PDT.

43

44 **Keywords:** Metallosurfactants, catanionic vesicles, methylene blue, singlet oxygen,  
45 photodynamic therapy

## 46 **1. Introduction:**

47 Photodynamic therapy (PDT) is a non-invasive fourth modality treatment approved by the  
48 FDA for the treatment of a variety of cancers [1]. The principal advantage of PDT over  
49 traditional chemotherapy or radiotherapy is its non-invasive nature and negligible side effects  
50 as oxidative damage only occur in the proximity of the PS [2-4]. In general, PDT requires a  
51 combination of three non-chemotoxic essential components viz. photosensitizer (PS), the  
52 light of specific wavelength, and molecular oxygen ( $^3\text{O}_2$ ). PDT relies on the generation of  
53 reactive oxygen species (ROS) from a photosensitizer upon activation by light of a specific  
54 wavelength, which eventually induces membrane damage and cell death [5,6]. ROS are  
55 generated either through charge transfer which generates radicals and superoxide (type I  
56 mechanism of PDT). In the type II mechanism, singlet oxygen ( $^1\text{O}_2$ ) is generated due to the  
57 transfer of energy from the excited triplet state of the PS to  $^3\text{O}_2$ . Therefore, achieving high  
58 efficiency of  $^1\text{O}_2$  generation from PS is one of the most important prerequisites for clinical  
59 application of PDT [7,8].


60 In recent years, a range of PSs such as PPIX, phthalocyanine, and verteporfin has been  
61 explored for PDT and a few of them have been approved by FDA for their use in clinics [1].  
62 However, most of these PSs are hydrophobic with absorption maxima in UV which causes  
63 poor bioavailability and limited penetration depth that leads to diminished PDT efficiency in  
64 clinical settings [7,8]. On the other hand, Methylene Blue (MB) is a tricyclic phenothiazine  
65 cationic dye approved for the treatment of methemoglobinemia. Due to its photophysical  
66 properties such as broad absorption band (550-700 nm) with absorption maxima at 664 nm  
67 and excellent solubility in physiologically relevant media it has been extensively studied for  
68 PDT against different cancers and bacterial infection. However, under physiological  
69 conditions, MB forms aggregate to form dimers which significantly reduces its ability to  
70 generate  $^1\text{O}_2$  thus impacting its therapeutic effectiveness [9,10]. Therefore, the design and

71 formulation of new biocompatible delivery vehicles that allow the encapsulation of MB at an  
72 adequate therapeutic level without affecting its chemical and photophysical properties are of  
73 great importance.

74 To date, many nanoscale delivery vehicles have been investigated and among them, vesicles  
75 have always been one of the preferred choices due to stable and have the ability for further  
76 improved chemical functionalization and physiological applications [11]. Mixing of  
77 cationic/anionic surfactant in a non-equimolar ratio leads to the spontaneous formation of a  
78 catanionic mixture which is known as catanionic vesicles (CVs) [12,13]. These catanionic  
79 vesicles have interesting physicochemical properties such as adjustable size, surface charge,  
80 and high permeability to skins by varying the cationic/anionic ratio and surfactant chain  
81 length [14-16]. Hybrid stimuli-responsive CVs can also be prepared by using pH, redox, and  
82 temperature-sensitive cationic and anionic surfactant for encapsulation of both  
83 hydrophilic/hydrophobic and cationic/anionic drugs for drug delivery applications [17]. On  
84 the other hand, metallosurfactants are hybrid surfactants that are prepared via the  
85 incorporation of metal into the molecular structure of surfactants [18]. Our group has  
86 previously reported different single and double-chain cationic metallosurfactant based nano-  
87 colloids for various applications for instance in catalysis, anti-corrosion, and drug delivery  
88 [19-22]. These metallosurfactant surfactants have gained considerable interest due to the  
89 dual inherent properties of metal and surfactant which self-assembled at low concentration as  
90 compared to parent surfactant. By using these metallosurfactant as cationic components a  
91 new hybrid metallocatanionic vesicles (MCVs) are synthesized, which carry dual metal and  
92 surfactant with both cationic and anionic surface charge.

93 Herein, we report the synthesis of MCVs from single-chain Iron-metal based surfactant i.e.  
94 hexadecyl pyridinium trichloro ferrate  $[Cp]^+[FeCl_3]^-$  (FeCPC I) combined with anionic  
95 single-chain sodium oleate (Na-OI) fatty acid. These synthesized vesicles were characterized

96 by dynamic light scattering (DLS), cryo-transmission electron microscope (cryo-TEM), and  
 97 field emission gun scanning electron microscopy (FEG-SEM). These MCVs were then used  
 98 for the delivery of cationic PS (MB) for photodynamic therapy of MCF-7 breast cancer cell  
 99 lines. Furthermore, the capability of MB-loaded vesicles to generate  $^1\text{O}_2$  in solution and  
 100 intracellularly was evaluated using 9, 10-anthracenediyl-bis(methylene) dimalonic acid  
 101 (ABMA) and singlet oxygen sensor green (SOSG), respectively. These MB-loaded FeCPC I:  
 102 Na-OI showed negligible toxicity under dark, while on the other hand, an enhanced  $^1\text{O}_2$   
 103 generation and the cell-killing effect was observed upon irradiation with a deep red laser (650  
 104 nm) for 10 min. To the best of our knowledge, this is the first study that reports on the  
 105 application of metallocatanionic vesicles for  $^1\text{O}_2$  mediated photodynamic therapy against  
 106 cancer cells.



107

108 **Scheme 1.** Schematic representation of metallocatanionic vesicles formation from FeCPC I:  
 109 Na-OI and subsequent loading of MB and their uses in photodynamic therapy.

## 110 2. Experimental section

### 111 2.1. Materials

112 All the chemicals used were of analytical grade and were used as supplied without further  
113 purification and modifications unless specified. Sodium Oleate [C<sub>18</sub>H<sub>33</sub>NaO<sub>2</sub>] Na Ol,  
114 Methylene Blue (MB), 9,10-Anthracenediyl-bis(methylene) dimalonic acid (ABMA), Cell  
115 Counting Kit-8 (WST-8) and Propidium Iodide (PI) were purchased from Sigma Aldrich  
116 (UK). Singlet Oxygen Sensor Green (SOSG) and Hoechst 33342 were purchased from  
117 Thermo Fischer Scientific, UK.

## 118 **2.2. Methodology**

119 **2.2.1 Synthesis of metallocatanionic vesicles:** Single-chain cationic iron metal-based  
120 metallosurfactant (hexadecylpyridinium iron (II) trichloride; FeCPC I) was prepared by  
121 following a protocol previously reported [23]. In brief, MCVs were synthesized using single-  
122 chain cationic metallosurfactant (FeCPC I) in combination with anionic single chain fatty  
123 acids Na Ol. A 1 mM solution of cationic and anionic surfactant was prepared separately in  
124 PBS. The solution was sonicated for 10 min and then mixed in different ratios of FeCPC I:Na  
125 Ol from 10:90 to 90:10. Finally, a gentle shaking for 10 min led to the formation of vesicular  
126 aggregates. In the manuscript, FeCPC I:Na Ol vesicle are represented as V19 or fraction  
127 (10:90) which consists of 10 % FeCPC I and 90% Na Ol and V91 or fraction (90:10) with  
128 90% FeCPC I and 10% Na Ol.

129 **2.2.2. Characterization of metallocatanionic vesicles:** Different techniques were used to  
130 characterize the fabricated vesicles. The mean hydrodynamic diameter (in nm),  
131 Polydispersity index (PDI), and zeta potential (mV) was estimated using Zetasizer Nano ZS  
132 (Malvern Panalytical, UK). The stability of these vesicles in PBS (pH = 7.4) was studied for a  
133 period of 1 month by measuring the hydrodynamic diameter and PDI. The morphology of  
134 colloidal structural aggregates of vesicles was characterized by cryo-TEM, JEOL 2100 plus  
135 TEM operating at 200kV, with the sample held at or below -176°C: images recorded using a  
136 Gatan US1000XP with a nominal defocus of 3-5 μm. The sample was prepared by depositing

137 3  $\mu$ L liquid onto a TEM grid (GO/C/300 mesh Cu) in a controlled environment (20°C, 78°  
138 humidity), blotting (1.5s) before plunging into liquid ethane to vitrify (Gatan CP3 cryo  
139 plunge). The sample was maintained under liquid nitrogen during storage and transfer to  
140 TEM using a Gatan 626 cryo holder and a Gatan (Smartest model 900) cold stage controller.  
141 The field emission gun scanning electron microscope (FEG-SEM) was utilized to study the  
142 surface morphology of the synthesized vesicles before and after loading the photosensitiser.  
143 A fresh sample of vesicles in PBS was casted on an aluminum stub and then dried overnight  
144 under vacuum. Later, the samples were coated with a 5 nm thick layer of iridium and finally  
145 imaged on JEOL 7100F operating at 5 kV. Fluorescence spectra of the MB-loaded MCVs  
146 were acquired using a FLS 980 spectrometer in a quartz cuvette. Next, Inductively coupled  
147 plasma mass spectroscopy (ICP-MS) (iCAPQ Thermo Fischer) study was performed to check  
148 the amount of Fe present in V73 and V37 fractions. Final MCVs fractions solution prepared  
149 2% HNO<sub>3</sub> acidic solution.

150 **2.2.3. MB encapsulation:** The encapsulation efficiency (%) of MB was evaluated using a  
151 protocol reported earlier [24,25]. MB solution was mixed with MCVs: V37 and V73 fractions  
152 and sonicated for 15 min and then kept for shaking for another 3 h. Finally, MB containing  
153 MCVs fractions were centrifuged at 13000 rpm followed by filtering. Fluorescence  
154 spectroscopy was used to record the fluorescence spectra of pure MB and MB-loaded MCVs.  
155 The encapsulation efficiency was calculated using the following equation:

$$156 \text{ Encapsulation efficiency (\%)} = (I_{\max} - I_0)/I_{\max} \times 100 \quad (1)$$

157 Where  $I_0$  is the fluorescence intensity of MB after loading into MCVs fraction and  $I_{\max}$  is the  
158 MB fluorescence intensity without MCVs.

159 Further, High resolution transmission electron microscope (HR-TEM) and FEG-SEM  
160 analysis were performed to check the MB@MCV V37 and V73 fractions morphology.

161 **2.2.4. Detection of Singlet oxygen generation by ABMA assay:** A chemical trapping  
162 method was used to evaluate the  $^1\text{O}_2$  generation capability of MB-loaded MCVs. For  
163 quantification of  $^1\text{O}_2$ , ABMA a water-soluble  $^1\text{O}_2$  trapping dye was used [26]. In brief,  
164 ABMA (2  $\mu\text{M}$ ) was mixed with either free MB or MB-loaded MCVs. The mixture was  
165 irradiated with a red diode laser (650 nm and 50 mW; purchased from ADLABS, India) for  
166 different periods of time. The efficiency of  $^1\text{O}_2$  generation was determined by monitoring the  
167 decrease in fluorescence emission intensity of the ABMA at 405 nm. Quantification of the  
168 generation of  $^1\text{O}_2$  as a function of percentage decay in ABMA fluorescence was calculated  
169 using the following equation:

170 The maximum rate of ABMA photobleaching = 
$$\frac{(\% \text{ IF at } t=0 \text{ sec}) - (\% \text{ IF at } t=60 \text{ sec})}{60 \text{ sec} \times \text{Methylene Blue } (\mu\text{M})} \quad (2)$$

171 Where, IF is the fluorescence intensity of ABMA at 405 nm.

172 **2.2.5. Cell culture-** Human breast cancer cells MCF-7(ATCC, USA) were cultured in high  
173 glucose Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine  
174 serum (FBS) from Gibco with 1% penicillin/streptomycin. Cells were maintained in a  
175 humidified incubator containing 5%  $\text{CO}_2$  at 37  $^\circ\text{C}$ .

176 **2.2.6. WST-8 metabolic activity assay -** A cell counting kit (CCK-8) was used to evaluate  
177 the dark and phototoxicity of MB-loaded MCVs on MCF-7 cells. For dark toxicity, a total of  
178  $5 \times 10^3$  cells/well were seeded in a 96 well plate and incubated for 24 h. Afterward, culture  
179 media was replaced with fresh media containing either MB (0.5 $\mu\text{M}$ ) or plain MCVs viz.V37  
180 and V73 or MB loaded vesicles at different concentrations (0.05, 0.1, 0.2, 0.5, and 0.75  $\mu\text{M}$ )  
181 and incubated for 24 h. The concentration of MB was fixed at 0.5  $\mu\text{M}$  in all the MCVs. Later,  
182 the cells were washed twice with PBS and 100  $\mu\text{L}$  fresh media was added and cells were  
183 further incubated for 24 h. Next, the media was replaced with a mixture of DMEM containing  
184 10 % CCK-8. The cells were incubated for 3 h at 37  $^\circ\text{C}$  and 5%  $\text{CO}_2$ . Finally, the absorbance  
185 of the plate was read at 450 nm using a Tecan microplate reader. All the experiments were

186 performed in triplicate and were repeated twice. For phototoxicity studies, the media of cells  
187 (24 h after seeding) was replaced with fresh media containing MB (0.5  $\mu\text{M}$ ) or MB  
188 containing vesicles V37 and V73 or plain vesicles at a concentration of 0.2 and 0.75  $\mu\text{M}$   
189 followed by 24 h incubation. Afterward, cells were washed twice with PBS and fresh media  
190 was added. Next, the plate was irradiated with a red laser (650 nm; power = 50 mW) at  
191 different doses and incubated for 24 h before measuring absorbance at 450 nm. Absorbance  
192 reading of untreated cells in the culture medium was used for baseline correction.

193 **2.2.7. Cellular uptake study-** For cell uptake analysis, MCF-7 cells were seeded in a 96-well  
194 plate at a density of  $5 \times 10^3$  cells/well and incubated for 24 h. Then, the culture media was  
195 replaced with fresh media containing either MB (2  $\mu\text{M}$ ) or MB-loaded vesicles (V37 and  
196 V73), and the plate was further incubated for another 24 h to facilitate the uptake of MCVs.  
197 Afterward, the cells were washed thrice with PBS to remove unbounded MB-loaded vesicles  
198 and incubated for another 24 h. Finally, the cells were fixed with 4% paraformaldehyde for  
199 15 min followed by Actin phalloidin stain for 30 min. and DAPI for 20 min. Between each  
200 staining step the cells were washed thrice with PBS. Finally, the plate was imaged using a  
201 fluorescence microscope (Nikon eclipse Ti) at 20X objective. The nuclei, actin, and MB were  
202 imaged using DAPI, FITC, and mPlum filters, respectively.

203 **2.2.8. *Invitro* singlet oxygen detection-** MCF-7 cells were seeded at a density of  $5 \times 10^3$   
204 cells/well in tissue culture-treated black glass-bottom 96-well plate and incubated for 24 h at  
205 37 °C and 5% CO<sub>2</sub> atmosphere. Next, the media of the cells was replaced with media  
206 containing either free MB (0.5  $\mu\text{M}$ ) or MB-loaded MCVs viz V73 and V37 at a concentration  
207 of 0.2 and 0.75  $\mu\text{M}$ . After 24 h of incubation, cells were washed twice with PBS and the  
208 media was replaced with SOSG (10  $\mu\text{M}$ ) in PBS solution and incubated for 20 min. Later,  
209 each well of the plate was irradiated with a 650 nm red diode laser for 10 min. Finally, the

210 cells were washed with PBS and the green fluorescence of SOSG was observed as a function  
211 of <sup>1</sup>O<sub>2</sub> generation using a Nikon eclipse Ti with FITC filter settings.


212 **2.2.9. DNS assay-** Hoechst/Propidium Iodide (PI) differential nuclear staining was performed  
213 to detect the % of dead cells. The cells were seeded at a density of 5×10<sup>3</sup> cells/well in 96 well  
214 glass bottom black plates. After 24 h incubation, the media was replaced with MB-loaded  
215 vesicles at a concentration of 0.75 μM and further incubated for 24 h. After the incubation  
216 period, the plate was washed with PBS and fresh media was added followed by irradiation  
217 with 650 nm laser for 10 min followed by incubation for another 4 h. Afterward, the cells  
218 were washed gently with PBS, and PI solution was added (0.25 mg/mL in PBS) and  
219 incubated for 10 min at room temperature. Next, the cells were washed with PBS twice and  
220 100 μL Hoechst was added to each well and left for 20 min at room temperature. Finally, the  
221 plate was imaged using a Nikon eclipse Ti fluorescent microscope with DAPI and mCherry  
222 filter settings.

### 223 **3. Result and Discussion:**

#### 224 **3.1. Preparation and characterization of MCVs:**

225 The cationic metallosurfactant was synthesized using a protocol reported earlier [23]. In brief,  
226 a ligand insertion synthesis method was employed which contained a 1:1 ratio of iron metal  
227 in combination with cetylpyridinium chloride (CPC). A facile and quick solution-solution  
228 mixing method with high reproducibility was utilized for the synthesis of MCVs. An anionic  
229 single-chain fatty acid was employed for the synthesis of MCVs fractions by mixing cationic  
230 metallosurfactant and an anionic surfactant. These cationic and anionic parts were dissolved  
231 in PBS (pH = 7.4) and sonicated for 10 minutes to obtain a homogenous solution and then  
232 finally mixed in different ratios, which spontaneously led to the formation of vesicles. Fig. 1  
233 (A) represents the cationic FeCPC I and anionic Na Ol component surfactant. Fig. 1(B)


234 shows FeCPC I:Na Ol (total 1 mM concentration) fractions from 1:9 to 9:1 ratio, labeled as  
 235 V19 to V91. The anionic rich fractions were more turbid while cationic rich fractions were  
 236 colored which is due to cationic FeCPC I. While Fig. 1(C) is for 0.1 mM concentration of  
 237 FeCPC I:Na Ol fractions which appeared to be clear on both cationic and anionic sides.



238  
 239 **Fig. 1 Metallocatanionic vesicles component surfactant and prepared fractions (A)**  
 240 Structure of FeCPC I and Na Ol component surfactant. Images of the fractions prepared from  
 241 FeCPC I:Na Ol (B) 1 mM and (C) 0.1 mM mixing in PBS solution. Where V19 and V91  
 242 indicate 10:90 and 90:10 fraction of FeCPC I:Na Ol mixture and so on.

243 The hydrodynamic diameter ( $D_h$ ) (in nm) and zeta-potential (in mV) are crucial parameters to  
 244 determine the nature (size and surface charge) of the cationic system. The size and zeta-  
 245 potential value of different fractions are presented in Fig. 2. Fig. 2(a&b) shows the change in  
 246  $D_h$  and zeta-potential of 1 mM FeCPC I:Na Ol fractions and Fig. 2(c&d) shows the change in  
 247  $D_h$  and zeta-potential of 0.1 mM vesicular fractions, respectively. Table S1 lists the value of  
 248 PDI at both concentrations for all fractions. These fractions behave similarly at both  
 249 concentrations. Exponential growth in the hydrodynamic diameter was observed for samples  
 250 with the increase in the proportion of cationic component of the metallosurfactant i.e. from  
 251 V19 to V91 fraction. For instance (Fig. 2(a)), at 1 mM fraction V19 exhibits the minimum  
 252 size (100 nm), whereas V91 the observed size was 700 nm. Zeta-potential of anionic rich

253 side carries anionic surface charge as expected: Zeta-potential value for fraction V19 to V37  
 254 showed a surface charge around -50 mV to -30 mV. All the other fractions have a positive  
 255 charge of around +55 mV which is due to the more cationic content in the mixture. Similarly,  
 256  $D_h$  and zeta-potential of 0.1 mM vesicular fractions calculated, for fractions (V19 to V73)  
 257 showed a size around 200 nm, however, with the increase in FeCPC I content in FeCPC I:Na  
 258 OI size increases to 500 nm and 650 nm for V82 and V91 fractions, respectively. (Fig. 2(c)).  
 259 For zeta-potential first three fractions (Fig. 2(d)) V19, V28, and V37 have charges around -40  
 260 mV while all other fractions carry a positive charge. PDI for all fractions other than V82 and  
 261 V91 is less than 0.5 which also indicates the monodispersity in the system (Table S1). The  
 262 obtained data confirmed that with an increase in metallosurfactant content in the total fraction  
 263 of FeCPC I:Na OI there was an increase in the size of the vesicular system. In general,  
 264 vesicles with zeta-potential that vary between + 30 mV to -30 mV not formed aggregates.  
 265 Most of these vesicular fractions have a zeta-potential of more than +30 mV or less than -30  
 266 mV which confirms that these synthesized MCVs have excellent colloidal stability.




267

268 **Fig. 2 DLS and Zeta-potential characterization of synthesized FeCPC I:Na-OI**  
269 **metalloctanionic vesicles fractions (a) size (nm) and (b) zeta-potential (mV) of FeCPC**  
270 **I:Na OI (1 mM), (c) size (nm) and (d) zeta-potential (mV) of FeCPC I:Na OI (0.1 mM).**

271 For further studies, two fractions were selected out of all the fractions at 0.1 mM. The  
272 spontaneous and stable octanionic vesicles always require one of the surfactants in excess that  
273 gives a net charge on vesicles that also cause significant colloidal stabilities [27]. One is from  
274 the anionic rich side i.e V37 and the other is the cationic rich side i.e V73 were chosen. These  
275 fractions exist in between on both sides from FeCPC I:Na OI equimolar ratio. Both these  
276 fractions have a size of less than 200 nm with good PDI (Table S1) The hydrodynamic  
277 diameter in PBS was monitored by DLS for one month (Table S2) at intervals, to estimate the  
278 stability of these selected V37 and V73 octanionic mixtures. Both fractions showed good  
279 stability order in solution for up to 1 month. For the V37 fraction, the vesicle's size on a  
280 freshly prepared sample was 142 nm and after a month it increases up to 253.8 nm with PDI  
281 less than 0.5 nm. In the case of V73, size and PDI almost remained close by for one month.  
282 After one week size does not seem to change in both fractions.

283 Cryo-TEM and FEG-SEM were employed to study the structural distribution, morphology,  
284 and integrity of the prepared vesicles on selected fractions V37 and V73. Samples for cryo-  
285 TEM were prepared at room temperature. Fig. 3 (a) and (b) show the uni-lamellar spherical  
286 structure of the V37 and V73 fractions, respectively. Fig. 3(c) and 3(d) showed the FEG-  
287 SEM images of V37 and V73 vesicular structures which further confirms the spherical  
288 morphology of the octanionic system. The size obtained from the cryo-TEM technique for  
289 V37 and V73 is smaller than the size obtained from the DLS. This is because the DLS  
290 technique gives estimated size by measuring the hydrodynamic diameter plus double liquid  
291 layer around the vesicles while cryo-TEM gives the actual estimate of particle size.



292


293 **Fig. 3 MCVs morphology characterization images**, Cryo-TEM images of (a) V37, and (b)  
 294 V73 (size bar 200 nm); FEG-SEM images of (c) V37, and (d) V73 fractions.

295 Next ICP-MS analysis was performed to check the amount of Fe present in the prepared V37  
 296 and V73 fractions. We have found that in V37 amount of Fe was 117.04  $\mu\text{g/L}$  and in the V73  
 297 fraction, it was 247.58  $\mu\text{g/L}$ . ICP-MS study revealed that metallosurfactant rich fractions  
 298 have more amount of Fe in comparison to Na Ol rich V37 fractions.

299 Fluorescence spectroscopy was utilized to characterize the encapsulation of MB into the  
 300 vesicles. Fluorescence emission spectra of MB loaded V37 and V73 vesicles fractions were  
 301 recorded and compared with the spectra of free MB to estimate the loading concentration.  
 302 There was a decrease in the fluorescence intensity of MB when we mixed them with  
 303 vesicular fractions (Fig. S2). By using encapsulation efficiency eq. 1 this change in PS  
 304 fluorescence emission spectra was calculated and MB encapsulation was found to be 12.05 %  
 305 and 20.30 % with V37 and V73 fractions, respectively, compared to free MB. This shows  
 306 that the metallosurfactant rich fraction has higher encapsulation as compared to Na Ol rich  
 307 (V37) fraction. Fig. S2 suggests that a higher decrease in fluorescence intensity for V73

308 vesicular fraction as compared to the V37 fraction. Furthermore, V37 and V73 vesicular  
309 fractions containing MB were characterized using zeta-potential measurement (Table S2).  
310 The empty vesicles V37 and V73 have zeta potential values of -38.1 mV and 28.5 mV,  
311 respectively. After loading with MB, the values fluctuated to -37 mV for V37 and +23 mV  
312 for the V73 fraction. These results suggest that cationic MB decreases the anionic surface  
313 charge of V37 fractions and the cationic surface charge of the V73 fraction and confirms  
314 successful encapsulation of MB.

315 Further stability of two selected MB@V37 and MB@V73 fractions were studied in acidic,  
316 neutral, and basic conditions. MB@V37 and MB@V73 fractions were prepared in 5, 7, and 9  
317 pH solutions and hydrodynamic size and PDI values were calculated by employing DLS for  
318 two week. The measured value of size and PDI are given in Table S3. This study confirmed  
319 that prepared MB@MCVs V37 and V73 fractions are stable in this studied condition. Their  
320 size and PDI values increased with time. In addition to this, MCV V37 and V73 fractions  
321 morphology was checked after loading MB. HR-TEM and FE-SEM analysis were performed.  
322 Fig. 4(a&b) shows the HR-TEM images of MB@V37 and MB@V73 fractions, respectively.  
323 Fig. 4(c&d) shows the FE-SEM images of MB@V37 and MB@V73 fractions, respectively.  
324 Both microscopy investigations confirmed that vesicles morphology remained undisturbed  
325 after PS loading into vesicles.




326

327 **Fig. 4 MB@MCVs morphology characterization images, HR-TEM images of MB with (a)**  
328 **V37, and (b) V73 (size bar 1  $\mu\text{m}$ ); FEG-SEM images of MB with (c) V37, and (d) V73**  
329 **fractions.**

330 Also, the FEG-SEM study was carried for MB@V37 and MB@V73 fractions at the above-  
331 studied pH environment. Fig. S2(a-c) shows the FEG-SEM images of MB@V37 and  
332 MB@V73 fractions at 5, 7 and 9 pH. HR-TEM analysis was also performed on  
333 metallosurfactant rich cationic charge carried MB@V73 fraction at same pH environment.  
334 Fig. S3(a-c) shows the HR-TEM images of the MB@V73 fraction at 5, 7, and 9 Ph,  
335 respectively. This microscopic study confirmed that in this studied pH environment condition  
336 prepared MB@MCVs fractions were remained stable.

337 **3.2. In-situ Singlet Oxygen Generation:** The efficiency of MB-loaded MCVs to produce  
338  $^1\text{O}_2$  upon irradiation with red laser was evaluated using ABMA assay. ABMA is a well-  
339 known water-soluble dye that shows high sensitivity towards  $^1\text{O}_2$ , which can be monitored by  
340 following the quenching in fluorescence emission intensity. Upon excitation with 650 nm  
341 laser for 2 min, ABMA alone or empty V37 and V73 samples did not show any quenching in  
342 the fluorescence intensity of ABMA suggesting these samples do not generate any  $^1\text{O}_2$  (Fig.  
343 5a and S4 a-c). On the other hand, MB alone (0.5  $\mu\text{M}$ ) or the MCVs loaded with MB showed  
344 a significant decrease in ABMA fluorescence suggesting  $^1\text{O}_2$  generation. Importantly, MB-  
345 loaded vesicles produced more  $^1\text{O}_2$  generation compared to MB alone (Fig. 5a and S4 d-f).  
346 This could be due to the presence of metal ions within the cationic vesicles, which have  
347 been shown to enhance  $^1\text{O}_2$  generation by reducing the self-quenching caused by the  
348 aggregation of MB as well as by improving the photophysical properties of the MB by  
349 promoting the intersystem crossing, triplet PS<sup>3</sup> quantum yield and fluorescence lifetime in the  
350 excited state. Therefore, based on the obtained data, it can be concluded that these Fe-  
351 metallocationic vesicles enhance the efficiency of  $^1\text{O}_2$  generation from MB [28,29].



352

353 **Fig. 5 Red light-mediated generation of singlet oxygen from MB-loaded**  
 354 **Metallocatanionic vesicles. (a)** Time-dependent singlet oxygen generation as a function of  
 355 change in fluorescence intensity of ABMA (at 405 nm) from different MCVs. **(b)** Rate of  
 356 change in ABMA photobleaching for a period of 60 sec per PS concentration.

357 The time-dependent changes in ABMA fluorescence intensity after irradiation in different  
 358 samples are plotted in Fig. 5(a). This shows an extremely fast and high decrease in ABMA  
 359 fluorescence emission intensity when MB was encapsulated to V73 as compared to V37 and  
 360 pure MB. This rate of ABMA photobleaching was calculated per 60 sec and per MB (2  $\mu\text{M}$ )  
 361 concentration (Fig. 5(b)) by using a reported formula [30,31].


362 The percentage rate of ABMA photobleaching for various combinations under irradiation is  
 363 given in Fig. 5(b). The results confirmed that there was no effect of laser on ABMA as the  
 364 percentage rate of ABMA photobleaching was 0.01 % The value reaches 0.030 % and  
 365 0.077% with V37 and V73 fractions, respectively when empty vesicles were used, and this  
 366 implies that an insignificant amount of  $^1\text{O}_2$  was generated from pure vesicles. % rate of  
 367 ABMA photobleaching was 0.5 % when pure MB was used under irradiation. While, it  
 368 increases to 0.58% and 0.70%, for MB-loaded vesicles V37 and V73, respectively. For MB  
 369 with V37 and V73 fractions, there was a 0.1-fold and 0.40-fold increase in the  $^1\text{O}_2$  generation  
 370 was observed, respectively These results indicate that there was an increase in  $^1\text{O}_2$  efficiency

371 of pure MB after loading in the vesicles system and this increase was more with the V73  
372 vesicular system as compared to V37.

### 373 **3.3 *In vitro* studies:**

374 **3.3.1 Biocompatibility, photodynamic therapy, and cellular uptake:** Encouraged by the  
375 *in-situ*  $^1\text{O}_2$  generation capability of the MCVs synthesized in this work, we next evaluated the  
376 biocompatibility, photo-toxicity and cellular uptake of these MB loaded MCVs in MCF-7  
377 cells. Firstly, the dark toxicity (no laser irradiation) of the free MB, empty and MB-loaded  
378 MCVs incubated with MCF-7 cells for 48 h was evaluated using WST-8 metabolic activity  
379 assay at various concentrations (0.5  $\mu\text{M}$  to 0.75 $\mu\text{M}$ ) (Fig. 6(a)). These empty and MB-loaded  
380 MCVs showed a negligible reduction in metabolic activity of MCF-7 cells under dark,  
381 suggesting the non-toxic nature of these MCVs even a high concentration of 0.75  $\mu\text{M}$ . While  
382 comparing the toxicity of these MCVs with free MB and the untreated control group we  
383 found that there was no significant change in metabolic activity. Next, we analyzed the  
384 photodynamic effect of the MCVs (0.2  $\mu\text{M}$  and 0.75  $\mu\text{M}$ ) incubated with MCF-7 cells by  
385 illuminating the cells with a red diode laser (650 nm and 50 mW) for 10 min. All the MB-  
386 loaded MCVs showed a concentration-dependent significant decrease in metabolic activity  
387 compared to untreated control. While MB-loaded V73 MCVs caused a 40% and 80%  
388 decrease in metabolic activity, the V37 MCVs reduced the metabolic activity of MCF-7 cells  
389 by 25% and 50% at a concentration of 0.2 and 0.75  $\mu\text{M}$ , respectively (Fig. 6(b)).  
390 Interestingly, MB-loaded V73 MCVs showed higher phototoxicity compared to the V37  
391 control. Furthermore, free MB and empty vesicle did not elicit any changes in the metabolic  
392 activity, suggesting the MCVs mediated the enhanced phototoxic effect of MB. To analyze  
393 whether the distinct susceptibility to MB-loaded vesicles was due to differences in their  
394 uptake, we analyzed the intracellular level of MB fluorescence using a fluorescence  
395 microscope (Fig. 6(c-f)). After incubation with MB-loaded MCVs, MCF-7 cells were fixed

396 and counterstained with DAPI (blue) and actin tracker (green) in order to evaluate the proper  
 397 localization of red fluorescence of MB-loaded MCVs. Overlapping MB and actin  
 398 fluorescence were observed within the cells treated with free MB or MB-loaded MCVs,  
 399 suggesting their uptake within MCF-7 cells. Strong fluorescence was observed in cells  
 400 incubated with V73 MCVs (Fig. 6(d)) compared to V37 MCVs or MB alone (Fig. 6(e&f)).  
 401 This higher uptake of V73 compared to V37 MCVs could be due to the presence of a higher  
 402 cationic component which results in a zeta potential of + 23 mV versus -37 mV for V37,  
 403 which causes an enhanced electrostatic interaction with MCF-7 cells (zeta potential = -20  
 404 mV) [32,33]. Furthermore, similar to previously reported literature a poor cellular uptake of  
 405 MB was observed [34]. This distinct cellular uptake profile explains the obtained difference  
 406 in the photo-toxicity of free MB and MB-loaded V73 & V37 MCVs. Thus, based on the  
 407 obtained data it can be concluded that the MCVs are biocompatible PS delivery vehicles,  
 408 which due to their cationic nature improves the uptake of MB and enhances the efficiency  
 409 of PDT due to the presence of a metal ion.




410

411 **Fig. 6 In vitro cytotoxicity and uptake of MB-loaded MCVs in MCF-7 cells.** (a) Dark  
412 toxicity and (b) photo-toxicity of MB-loaded MCVs at various concentrations were analyzed  
413 using WST-8 assay upon exposure with a red laser (650 nm, 50 mW) for 10 min. The  
414 experiment was performed using triplicates and the data are expressed as mean  $\pm$  S.E.M.  
415 Statistical significance at \*\*\*\*p < 0.0001 vs untreated control (denoted as C) was calculated  
416 using 2-way ANOVA with Tukey post-test. (c-f) Cellular uptake of MB-loaded MCVs was  
417 analyzed using a fluorescence microscope. DAPI (blue) – nucleus, actin (green) –  
418 cytoskeleton and red - MB-loaded MCVs. Scale bars = 100  $\mu$ m.

419 In literature, there was only one article available, for use of CVs in PDT. Castagnos *et al.*  
420 reported the use of lactose-derived tricatener based CVs for chloroaluminium phthalocyanine  
421 (CIAIPc) PS delivery and applied *in vitro* PDT on melanoma cell line (B16-F10) and oral  
422 squamous cell carcinoma (OSCC) cell lines. In this article, they have not discussed the *in situ*  $^1\text{O}_2$   
423 generation ability of CIAIPc alone and after loading into CVs. However, they found an increase  
424 in *in vitro* phototoxicity against both cell lines [35]. This prepared FeCPC I:Na OI MCVs  
425 formulation enhanced the both *in situ*  $^1\text{O}_2$  generation ability of MB and also it enhanced the *in*  
426 *vitro* phototoxicity against MCF-7 cells.

427 **3.3.2. Intracellular  $^1\text{O}_2$  generation and cancer cell killing effect of MB loaded MCVs:** To  
428 confirm intracellular  $^1\text{O}_2$  generation, MCF-7 cells were incubated MB loaded MCVs before  
429 red laser irradiation and  $^1\text{O}_2$  generation was detected using SOSG, which is converted to a  
430 fluorescent green derivative (endoperoxide) upon reactive with  $^1\text{O}_2$ , immediately after 10 min  
431 laser exposure. Strong green fluorescence was observed in all the MCVs samples, on the  
432 other hand, free MB and untreated cells showed very weak and no fluorescence, respectively  
433 (Fig. 7(a)). Both MB-loaded V73 and V37 MCVs showed a concentration-dependent increase  
434 in  $^1\text{O}_2$  generation. However, V73 MCVs showed a substantial  $^1\text{O}_2$  generation, this could be  
435 attributed to higher uptake of V73 fraction compared to V37 MCVs.  $^1\text{O}_2$  generation was

436 quantified by calculating the integrated fluorescence intensity per area of the fluorescence  
 437 image using ImageJ [36] (Fig. 7(b)). The obtained data indicate V73 and V37 MCVs produce  
 438 significantly higher  $^1\text{O}_2$  as compared to free MB, respectively. This implies that MB-loaded  
 439 MCVs mediated enhancement in intracellular  $^1\text{O}_2$  generation. Fig. S5 showing the overlay of  
 440 dark and fluorescence images of SOSG fluorescence.




441  
 442 **Fig. 7 Intracellular  $^1\text{O}_2$  generation in MCF-7 cells treated with MB-loaded MCVs upon**  
 443 **irradiation with 650 nm laser for 10 min. (a) Fluorescent microscopy images showing  $^1\text{O}_2$**   
 444 **generation from different MCVs. Scale bars = 100 μm. (b) Integrated fluorescence intensity**  
 445 **per area as a function of  $^1\text{O}_2$  generation.**

446 Next, to confirm  $^1\text{O}_2$  mediated membrane damage and cell death, we performed DNS assay  
 447 4h after 10 min PDT. This assay is based on staining the nucleus using two different DNA

448 intercalating dyes viz. Hoechst 33342 and Propidium iodide (PI). Hoechst was used to stain  
449 the nucleus of all cells (dead or alive) thus represent the total number of cells, while, on the  
450 other hand, PI was used to stain the DNA of only dead cells caused by  $^1\text{O}_2$  mediated  
451 membrane damage [37]. A few red spots corresponding to the fluorescence of PI were  
452 observed in cells treated with MB alone, while no fluorescence was detected in the untreated  
453 control group (Fig. 8(a&b)). The high fluorescence signal of PI was observed in cells treated  
454 with MB-loaded V37 and V73 MCVs at a concentration of 0.75  $\mu\text{M}$  (Fig. 8(c&d)),  
455 suggesting MB-loaded MCVs increase cell death within 4h of PDT compared to MB alone.

456 Overall, these results show that Fe containing cationic vesicles not only facilitates the  
457 uptake of MB but also enhances the efficiency of  $^1\text{O}_2$  generation. Furthermore, combined  
458 with negligible dark toxicity, high photo-toxicity, deep red fluorescence of these Fe  
459 containing nano-sized colloidal vesicles a promising candidate for application in  
460 simultaneous imaging and delivery of other hydrophobic yet clinically important PSs for the  
461 PDT of deep-lying tumors.



462

463 **Fig. 8 Fluorescence microscopic images of live/dead MCF-7 cell line after stained with**  
464 **Hoechst(blue)/PI (red) after PDT in presence (a) control untreated cells, (b) MB, (c) MB-**

465 loaded V37 and (d) MB-loaded V73 vesicles fraction after laser light irradiation for 10 min.  
466 Blue and Red colors represent the DNA of cells and dead cells, respectively.

467 **4. Conclusions:** In summary, we synthesized MCVs using single-chain cationic iron-metal-  
468 based metallosurfactant (FeCPC I) in combination with anionic single-chain sodium oleate  
469 (Na Ol). These synthesized MCVs with fractions 70:30 (V73) and 30:70 (V37) showed  
470 excellent colloidal stability for a period of up to a month. Cryo-TEM and FEG-SEM analysis  
471 revealed V37 and V73 fractions show unilamellar structure with a size of 100 nm. In-situ  
472 singlet oxygen study showed that the synthesized MCVs enhanced the singlet oxygen  
473 generation efficiency of MB by improving its photophysical properties. This increase was  
474 higher with metallosurfactant dominant fraction i.e V73 as compared to V37. The MCVs  
475 further enhanced the rate of ABMA photobleaching by pure MB alone when loaded in  
476 metallocatanionic vesicles suggesting the vital role of metallosurfactant in singlet oxygen  
477 enhancement of MB. Finally, these MB-loaded vesicles systems were applied for *invitro* PDT  
478 of MCF-7 human breast cancer cells. The synthesized MCVs showed negligible dark toxicity  
479 while on the other hand after irradiation with diode laser light (wavelength 650 nm, power 50  
480 mW) for 10 min MB-loaded V73 MCVs caused a significant reduction (nearly 80%) in  
481 metabolic activity of MCF-7 cells by as compared to the V37 MCVs and free MB. Moreover,  
482 intracellular  $^1\text{O}_2$  generation and different nuclear staining analyses revealed that the MB-  
483 loaded metallosurfactants based FeCPC I: Na Ol MCVs enhance singlet oxygen mediated  
484 cancer cell death within 4h after irradiation with 650 nm light. The presence of cationic and  
485 anionic charges on these vesicles increases the future research opportunities of these  
486 formulations in different drug delivery systems. Although, the PDT effects of MB-loaded  
487 MCVs in cancer treatment will need further justification through animal study.

488 **Supporting information:** Table S1. List of the PDI value calculated for all fractions at 1 mM  
489 and 0.1 mM concentration. Table S2. Metallocatanionic vesicles measured size and PDI

490 value of V37 and V73 fraction till 1 month. Fig. S1. Fluorescence emission spectra of free  
491 MB and MB containing vesicles. Fig. S2. Fluorescence emission spectra of ABMA after  
492 different treatments (a) only Laser (L) (b) only V73+ L (c) V37+ L (d) MB + L (e) MB +  
493 V37 + L (f) MB + V73 + L Fig. S3. Intracellular singlet oxygen generation in MCF-7 cells  
494 treated with MB-loaded MCVs upon irradiation with 650 nm laser for 10 min. Overlay  
495 images (fluorescent microscopy + Bright field) showing  $^1\text{O}_2$  generation from different MCVs.  
496 Scale bars = 100  $\mu\text{m}$ .

497 **ORCID:**

498 Bunty Sharma: 0000-0003-2495-6288

499 Akhil Jain: 0000-0003-2019-2030

500 Lluisa Perez-Garcia: 0000-0003-2031-4405

501 Frankie J. Rawson: 0000-0002-4872-8928

502 Ganga Ram Chaudhary: 0000-0003-0501-6071

503 Gurpreet Kaur: 0000-0002-8985-3186

504 **Author Contributions:**

505 Bunty Sharma and Akhil Jain have contributed equally to this work. **Experimental planning,**  
506 **design, and execution:** B.S., A.J., and G.K. **Original draft:** B.S. and A.J. **Data Analysis:**  
507 B.S., A.J., and J. A. W. **Reviewing and editing:** B.S., A.J., L.P.G, F.J.R., G.R.C., and G.K.  
508 **Resources:** L.P.G., J. A. W., F.J.R., G. R. C., and G. K. **Supervision:** G.K., G.R.C., and  
509 L.P.G. **Funding:** G.K., G.R.C., L.P.G., and F.J.R.

510 **Acknowledgment:** B. Sharma wants to thank Commonwealth split-site scholarship (INCN-  
511 2019-409) and DST Inspire SRF (IF170098). G. Kaur is thankful to DST for INSPIRE

512 faculty award (IFA-12-CH-41). G. R. Chaudhary is thankful to UGC, India for INDO-US 21<sup>st</sup>  
513 century knowledge initiative project [F. No. 194-2/2016(IC)]. This work was supported by  
514 the European Regional Development Fund (FEDER) Spanish government grant PID2020-  
515 115663GB-C32. This work was also supported by the Engineering and Physical Sciences  
516 Research Council [Grant numbers EP/R004072/1, EP/L022494/1]. The authors would like to  
517 thank the Nanoscale and Microscale Research Centre (NMRC), the University of Nottingham  
518 for instrumentation and facility provided.

519

520 **Conflicts of interest:** There are no conflicts to declare.

521

## Reference-

- [1]. R. Baskaran, J. Lee, and S. G. Yang, *Biomater. Res.*, 2018, **22**, 25.
- [2]. J. Xiao, H Cong, S. Wang, B. Yu and Y. Shen, *Biomater. Sci.*, 2021, **9**, 2384-2412.
- [3]. Z. Zhou, J. Song, L. Nie, and X. Chen, *Chem. Soc. Rev.*, 2016, **45**, 6597-6626.
- [4]. X. Deng, Z. Shao, and Y. Zhao, *Adv. Sci.*, 2021, **8**, 2002504.
- [5]. S. Benson, F. de Moliner, A. Fernandez, E. Kuru, N. L. Asiimwe, J. S. Lee, L. Hamilton, D. Sieger, I. R. Bravo, A. M. Elliot, Y. Feng, and M. Vendrell, *Nat. Commun.*, 2021, **12**, 2369.
- [6]. L. Cheng, C. Wang, L. Feng, K. Yang, and Z. Liu, *Chem. Rev.*, 2014, **114**, 10869-10939.
- [7]. X. Zhao, J. Liu, J. Fan, H. Chao, and X. Peng, *Chem. Soc. Rev.*, 2021, **50**, 4185-4219.
- [8]. F. Akhtar, A. U. Khan, L. Misba, K. Akhtar, and A. Ali, *Eur. J. Pharm. Biopharm.*, 2021, **160**, 65-76.
- [9]. L. Sun, W. Jiang, H. Zhang, Y. Guo, W. Chen, Y. Jin, H. Chen, K. Du, H. Dai, J. Ji, and B. Wang, *ACS Appl. Mater. Interfaces*, 2019, **11**, 2302-2316.
- [10]. J. P. Tardivo, A. D. Giglio, C. S. de Oliveira, D. S. Gabrielli, H. C. Junqueira, D. B. Tada, D. Severino, R. F. Turchiello, and M. S. Baptista, *Photodiagnosis Photodyn Ther.*, 2005, **2**, 175-191.
- [11]. T. Bollhorst, K. Rezwan, and M. Maas, *Chem. Soc. Rev.*, 2017, **46**, 2091-2126.

- [12]. M. Dubois, B. Deme, T. G. Krzywicki, J. C. Dedieu, C. Vautrin, S. Desert, E. Perez, T. Zemb, *Nature*, 2001, **411**, 672-675.
- [13]. V. V. Dhawan, and M. S. Nagarsenker, *J. Control Release*, 2017, **266**, 331-345.
- [14]. K. Tsuchiya, H. Nakanishi, H. Sakai, and M. Abe, *Langmuir*, 2004, **20**, 2117-2122.
- [15]. J. Liu, Y. Jiang, Y. Cui, C. Xu, X. Ji, and Y. Luan, *Int. J. Pharma.*, 2014, 560-571.
- [16]. N. Manghisi, C. Leggio, A. Jover, F. Meijide, N. V. Pavel, V. H. S. Tellini, J. V. Tato, R. G. Agostino, L. Galantini, *Angew. Chem. Int. Ed.*, 2010, **49**, 6604-6607.
- [17]. W. Li, T. Luo, Y. Yang, X. Tan, and L. Liu, *Langmuir*, 2015, **31**, 5141-5146.
- [18]. P. Gong, Z. Chen, Y. Chen, W. Wang, X. Wang, and A. Hu, *Chem. Commun.*, 2011, **47**, 4240-4242.
- [19]. Pradeep, G. Kaur, G. R.; Chaudhary, and U. Batra, *J. Colloid Interface Sci.*, 2020, **562**, 598-607.
- [20]. B. Sharma, V. Thakur, G. Kaur, and G. R. Chaudhary, *ACS Appl. Bio. Mater.*, 2020, **3**, 8515-8524.
- [21]. H. Mehta, G. Kaur, G. R. Chaudhary, and U. Batra, *Corros. Sci.*, 2021, **179**, 109102.
- [22]. P. Kaushik, G. Kaur, G. R. Chaudhary, and U. Batra, *J. Colloid Interface Sci.*, 2021, **582**, 894-905.
- [23]. G. Kaur, P. Garg, B. Kaur, G. R. Chaudhary, S. Kumar, N. Dilbaghi, P. A. Hassan, and S. L. Gawali, *Soft Matter*, 2018, **14**, 5306-5318.
- [24]. R. C. F. G.; Lopes, O. F. Silvestre, A. R. Faria, M. L. C. do Vale, E. F. Marques, and J. B. Nieder, *Nanoscale*, 2019, **11**, 5932-5941.
- [25]. S. Geng, Y. Wang, L. Wang, T. Kouyama, T. Gotoh, S. Wada, and J. Y. Wang, *Sci. Rep.*, 2017, **7**, 39202-39215.
- [26]. N. A. Kuzbetsova, N. S. Gretsova, O. A. Yuzhakova, V. M. Negrimovskii, O. L. Kaliya, and E. A. Luk'yanets, *Russ. J. Gen. Chem.*, 2001, **71**, 36-41.
- [27]. S. A. Safran, P. Pincus, and D. Andelman, *Science*, 1990, **248**, 354.
- [28]. A. Steinegger, Y. Moritz, and S. M. Borisov, *J. Photochem. Photobiol. A*, 2021, **407**, 113046-
- [29]. L. B. Josefsen, and R. W. Boyle, *Met. Based Drugs*, 2008, **2008**, 276109.
- [30]. O. Penon, M. J. Marin, D. A. Russell, L. Pérez-García, *J. Colloid Interface Sci.*, 2017, **496**, 100-110.

- [31]. O. Penon, M. J. Marin, D. B. Amabilino, D. A. Russell, L. Pérez-García, *J. Colloid Interface Sci.*, 2016, **462**, 154-165.
- [32]. Y. Zhang, M. Yang, J. H. Park, J. Singelyn, H. Ma, M. J. Sailor, E. Ruoslahti, M. Ozkan, and C. Ozkan, *Small*, 2009, **5**, 1990-1996.
- [33]. O. V. Bondar, D. V. Saifullina, I. I. Shakhmaeva, I. I. Mavlvutova, and T. I. Abdullin, *Acta Naturae*, 2012, **4**, 78-81.
- [34]. P. T. Wu, C. L. Lin, C. W. Lin, N. C. Chang, W. B. Tsai, and J. Yu, *Nanomaterials*, 2018, **9**, 14.
- [35]. P. Castagnos, M P. Siqueira-Moura, P. L. Goto, E. Perez, S. Franceschi, I. Rico-Lattes, A. Tedesco and M. Blanzat, *RSC Adv.* 2014, **4**, 39372-39377.
- [36]. A. Jain, P. G. J. Pournier, V. Mendoza-Lavaniego, P. Sengar, F. M. Guerra-Olvera, E. Iniguez, T. G. Kretzschmar, G. A. Hirata, and P. Juarez, *J. Nanobiotechnology*, 2018, **16**, 26.
- [37]. M. E. Alea-Reyes, O. Penon, P. G. Calavia, M. J. Marin, D. A. Russell, L. Perez-Garcia, *J. Colloid Interface Sci.*, 2018, **521**, 81-90

**Graphical abstract:**

